Home > News > Q10: Stuart Hendry, CEO at Sphere Medical
September 5th, 2007
Q10: Stuart Hendry, CEO at Sphere Medical
Abstract:
Sphere, which was founded in 2002, is combining its patented microtechnology and nanotechnology to develop unique dice-sized microanalysers capable of measuring several key compounds such as, glucose, blood gases and drugs, simultaneously at low cost. Mortality in critical care remains unacceptably high, with associated costs of £billions annually. Real time measurement of drugs and physiological parameters, facilitating tight control of therapy, has been shown to dramatically improve patient outcomes, saving lives and money. Unfortunately, cost effective products to achieve this ideal are not currently available.
Source:
businessweekly.co.uk
Bookmark:
| Related News Press |
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Nanophotonic platform boosts efficiency of nonlinear-optical quantum teleportation April 25th, 2025
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||